113 related articles for article (PubMed ID: 2976280)
1. The synthetic retinoid fenretinide does not affect circulating hormone concentrations.
Secreto G; Costa A; Recchiane C; Pizzichetta M; Ballerini P
Breast Cancer Res Treat; 1988 Dec; 12(3):315-6. PubMed ID: 2976280
[No Abstract] [Full Text] [Related]
2. Lack of correlation between plasmatic levels of retinol and RBP and thyroid hormones in breast cancer patients treated with the synthetic retinoid fenretinide.
Pizzichetta M; Formelli F; Bombardieri E; Bruni GF; Costa A
Int J Biol Markers; 1990; 5(4):208. PubMed ID: 2151235
[No Abstract] [Full Text] [Related]
3. Distribution of fenretinide in the mammary gland of breast cancer patients.
Mehta RG; Moon RC; Hawthorne M; Formelli F; Costa A
Eur J Cancer; 1991; 27(2):138-41. PubMed ID: 1827276
[TBL] [Abstract][Full Text] [Related]
4. Factors affecting plasma retinol decline during long-term administration of the synthetic retinoid fenretinide in breast cancer patients.
Torrisi R; Parodi S; Fontana V; Rondanina G; Formelli F; Costa A; Boccardo F; Decensi A
Cancer Epidemiol Biomarkers Prev; 1994 Sep; 3(6):507-10. PubMed ID: 8000302
[TBL] [Abstract][Full Text] [Related]
5. Long-term tolerability of fenretinide (4-HPR) in breast cancer patients.
Rotmensz N; De Palo G; Formelli F; Costa A; Marubini E; Campa T; Crippa A; Danesini GM; Delle Grottaglie M; Di Mauro MG
Eur J Cancer; 1991; 27(9):1127-31. PubMed ID: 1835622
[TBL] [Abstract][Full Text] [Related]
6. Circulating hormones and breast cancer risk in premenopausal women: a randomized trial of low-dose tamoxifen and fenretinide.
Johansson H; Bonanni B; Gandini S; Guerrieri-Gonzaga A; Cazzaniga M; Serrano D; Macis D; Puccio A; Sandri MT; Gulisano M; Formelli F; Decensi A
Breast Cancer Res Treat; 2013 Dec; 142(3):569-78. PubMed ID: 24241787
[TBL] [Abstract][Full Text] [Related]
7. Chronic oral administration of fenretinide, as a chemopreventive agent to breast cancer patients, does not affect plasma alpha-tocopherol concentration.
Formelli F; Clerici M; De Palo G; Costa A; Veronesi U
Ann Oncol; 1991 Jun; 2(6):446-7. PubMed ID: 1837481
[No Abstract] [Full Text] [Related]
8. Abnormal retinal function associated with fenretinide, a synthetic retinoid.
Kaiser-Kupfer MI; Peck GL; Caruso RC; Jaffe MJ; DiGiovanna JJ; Gross EG
Arch Ophthalmol; 1986 Jan; 104(1):69-70. PubMed ID: 2935125
[TBL] [Abstract][Full Text] [Related]
9. Plasma retinol level reduction by the synthetic retinoid fenretinide: a one year follow-up study of breast cancer patients.
Formelli F; Carsana R; Costa A; Buranelli F; Campa T; Dossena G; Magni A; Pizzichetta M
Cancer Res; 1989 Nov; 49(21):6149-52. PubMed ID: 2529028
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of fenretinide (N-[4-hydroxyphenyl]retinamide) in advanced breast cancer and melanoma.
Modiano MR; Dalton WS; Lippman SM; Joffe L; Booth AR; Meyskens FL
Invest New Drugs; 1990 Aug; 8(3):317-9. PubMed ID: 2148744
[TBL] [Abstract][Full Text] [Related]
11. The metabolite N-4-methoxyphenylretinamide is a major determinant of fenretinide induced decline of plasma insulin-like growth factor-1.
Torrisi R; Pensa F; Fontana V; Costa A; Decensi A
Eur J Cancer; 1995; 31A(3):420-1. PubMed ID: 7786612
[No Abstract] [Full Text] [Related]
12. Effect of 4-hydroxyphenylretinamide and retinoic acid on proliferation and cell cycle of cultured human breast cancer cells.
Marth C; Böck G; Daxenbichler G
J Natl Cancer Inst; 1985 Nov; 75(5):871-5. PubMed ID: 2932587
[TBL] [Abstract][Full Text] [Related]
13. Alteration of retinol-binding-protein concentrations by the synthetic retinoid fenretinide in healthy human subjects.
Dimitrov NV; Meyer CJ; Perloff M; Ruppenthal MM; Phillipich MJ; Gilliland D; Malone W; Minn FL
Am J Clin Nutr; 1990 Jun; 51(6):1082-7. PubMed ID: 2140925
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effects of fenretinide metabolites N-[4-methoxyphenyl]retinamide (MPR) and 4-oxo-N-(4-hydroxyphenyl)retinamide (3-keto-HPR) on fenretinide molecular targets β-carotene oxygenase 1, stearoyl-CoA desaturase 1 and dihydroceramide Δ4-desaturase 1.
Poliakov E; Samuel W; Duncan T; Gutierrez DB; Mata NL; Redmond TM
PLoS One; 2017; 12(4):e0176487. PubMed ID: 28448568
[TBL] [Abstract][Full Text] [Related]
15. In vitro interaction of fenretinide with plasma retinol-binding protein and its functional consequences.
Berni R; Formelli F
FEBS Lett; 1992 Aug; 308(1):43-5. PubMed ID: 1386578
[TBL] [Abstract][Full Text] [Related]
16. Breast tissue accumulation of retinamides in a randomized short-term study of fenretinide.
Sabichi AL; Modiano MR; Lee JJ; Peng YM; Xu MJ; Villar H; Dalton WS; Lippman SM
Clin Cancer Res; 2003 Jul; 9(7):2400-5. PubMed ID: 12855611
[TBL] [Abstract][Full Text] [Related]
17. N-(4-hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma.
Sheikh MS; Shao ZM; Li XS; Ordonez JV; Conley BA; Wu S; Dawson MI; Han QX; Chao WR; Quick T
Carcinogenesis; 1995 Oct; 16(10):2477-86. PubMed ID: 7586155
[TBL] [Abstract][Full Text] [Related]
18. Long-term effects of fenretinide, a retinoic acid derivative, on the insulin-like growth factor system in women with early breast cancer.
Decensi A; Johansson H; Miceli R; Mariani L; Camerini T; Cavadini E; Di Mauro MG; Barreca A; Gonzaga AG; Diani S; Sandri MT; De Palo G; Formelli F
Cancer Epidemiol Biomarkers Prev; 2001 Oct; 10(10):1047-53. PubMed ID: 11588130
[TBL] [Abstract][Full Text] [Related]
19. Long-term survival of adult mouse mammary glands in culture and their response to a retinoid.
Telang NT; Sarkar NH
Cancer Res; 1983 Oct; 43(10):4891-900. PubMed ID: 6224553
[No Abstract] [Full Text] [Related]
20. Chemoprevention of skin carcinogenesis by phenylretinamides: retinoid receptor-independent tumor suppression.
Xu H; Cheepala S; McCauley E; Coombes K; Xiao L; Fischer SM; Clifford JL
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):969-79. PubMed ID: 16467112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
